

# Bacterial Epidemiology and Antimicrobial Resistance Profiles of Respiratory Specimens of Children with Pneumonia in Hainan, China

Wenhui Mai<sup>1,2,\*</sup>, Yiwei Liu<sup>1,3,\*</sup>, Qiaoyi Meng<sup>1,3</sup>, Jianping Xu<sup>1,4</sup> , Jinyan Wu<sup>1,3,5</sup>

<sup>1</sup>Center for Science Experiments, Hainan Medical University, Haikou, Hainan Province, People's Republic of China; <sup>2</sup>Laboratory Department, Haikou Maternal and Child Health Hospital, Haikou, Hainan Province, People's Republic of China; <sup>3</sup>Department of Pathogen Biology, Hainan Medical University, Haikou, Hainan Province, People's Republic of China; <sup>4</sup>Department of Biology, McMaster University, Hamilton, Ontario, Canada; <sup>5</sup>Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Medical University, Haikou, Hainan Province, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Jianping Xu; Jinyan Wu, Email [jpxu@mcmaster.ca](mailto:jpxu@mcmaster.ca); [hy0303003@hainmc.edu.cn](mailto:hy0303003@hainmc.edu.cn)

**Purpose:** To investigate the bacterial species and antimicrobial susceptibility of respiratory specimens of children with pneumonia in Hainan, China.

**Methods:** A total of 5017 specimens, including 4986 sputum samples, 19 bronchoalveolar lavage fluid samples and 12 tracheal tube tip samples from hospitalized children with pneumonia from April 1, 2021 to March 31, 2022 were studied. All the bacterial isolates were identified and confirmed with the VITEK 2 system. Antimicrobial susceptibility of all isolates was determined using the Kirby-Bauer method or the VITEK 2 Compact automatic system, following the breakpoints recommended by the Clinical and Laboratory Standards Institute.

**Results:** A total of 996 bacterial isolates were collected and classified into 24 species. The top 10 most frequent species were *Haemophilus influenzae* (356 isolates, 35.7%), *Streptococcus pneumoniae* (128, 12.9%), *Moraxella catarrhalis* (114, 11.5%), *Escherichia coli* (89, 8.9%), *Staphylococcus aureus* (89, 8.9%), *Klebsiella pneumoniae* (82, 8.2%), *Acinetobacter baumannii* (31, 3.1%), *Pseudomonas aeruginosa* (28, 2.8%), *Enterobacter cloacae* (18, 1.8%), and *Streptococcus agalactiae* (13, 1.3%). 70.5% strains had the resistant (R) and/or intermediate (I) phenotypes to at least one of the tested drugs, with a large proportion (54.6%) showing resistance to two or more commonly used antibiotics. In addition, 60.5% (69/114) of *M. catarrhalis* strains and 42.9% (153/356) of *H. influenzae* strains produced  $\beta$ -lactamases while 19.1% (17/89) *E. coli* and 6.1% (5/82) *K. pneumoniae* strains produced extended-spectrum  $\beta$ -lactamases.

**Conclusion:** A diversity of pathogenic bacteria were isolated from the respiratory tract of children with pneumonia in Hainan, China. High-frequency resistance to first-line antimicrobial drugs was observed in Gram-negative and Gram-positive bacteria, including 544 isolates resistant to at least two antibiotics. Rapid identification and susceptibility testing should be implemented for children with bacterial pneumonia in Hainan before drug treatment is recommended.

**Keywords:** pneumonia, bacteria, antimicrobial resistance, children, multidrug-resistant bacteria

## Introduction

Pneumonia is one of the major causes of childhood morbidity and mortality globally.<sup>1</sup> In 2015, an estimated 921,000 children younger than 5 years old died of pneumonia in the world.<sup>2</sup> In China, due to general improvements in living conditions, better healthcare and improved vaccines, the estimates of clinical pneumonia in children decreased from 25.9% in 2000 to 8.4% in 2015.<sup>1,3,4</sup> However, an estimated >700,000 children are still hospitalized with pneumonia in China each year, representing a huge disease burden.<sup>1,5</sup> These hospitalized pneumonia cases are a major cause of morbidity in children.<sup>1,6</sup>

Bacteria such as *H. influenzae*, *S. pneumoniae* are common causes of pneumonia in children. Based on the 2015 Global Burden of Diseases (GBD) data approximately 64% of pneumonia deaths in children under 5-years old were due to bacterial infections.<sup>1,2</sup> For example, through direct transthoracic needle lung biopsy and autopsy, bacteria were found to be responsible for most pneumonia deaths in African children.<sup>7</sup> More recently, bacteria were also recognized as causes for secondary pulmonary infections associated with coronavirus disease (COVID-19), increasing morbidity and mortality of COVID patients.<sup>8</sup>

Antimicrobial resistance (AMR) is recognized as one of the most serious global threats to human health and is commonly associated with high morbidity and mortality rates and large medical cost burdens.<sup>9,10</sup> The World Health Organization (WHO) has highlighted that infections by antibiotic-resistant bacteria are responsible for around 700,000 deaths per year worldwide, if left to persist at the current rate, may lead to 10 million deaths in 2050.<sup>11</sup> In particular, several recent reports described increases in multidrug resistant (MDR) bacteria during the COVID-19 pandemic, with the rise in MDR bacteria rendering infections increasingly difficult to treat.<sup>12–23</sup> Common MDR bacteria include Vancomycin resistant *Enterococci* (VRE), methicillin (oxacillin) resistant *S. aureus* (MRSA) and certain Gram-negatives such as *E. coli* and *K. pneumoniae* producing extended-spectrum  $\beta$ -lactamases or carbapenem-resistant *Enterobacteriaceae* (CRE).<sup>24,25</sup> Options for treating patients with MDR bacterial infections are often extremely limited.

To effectively prevent and treat infections by MDR bacteria, including those causing pneumonia, we need accurate diagnosis of both the disease agents and their antimicrobial susceptibilities. However, at present, relatively little is known about the bacterial species and antimicrobial susceptibility of respiratory specimens from children with pneumonia, especially in tropical and developing regions such as in Hainan Island, South China. In this study, we aim to investigate the bacterial species and their susceptibilities to commonly used antimicrobial drugs of respiratory specimens from children with pneumonia in Haikou Maternal and Child Health Hospital in Hainan, China. The prevalence of MDR bacteria was also investigated in this study.

## Materials and Methods

### Samples

A total of 5017 specimens including 4986 sputum samples, 19 bronchoalveolar lavage fluid samples and 12 tracheal tube tip samples from hospitalized children with pneumonia from April 1, 2021, to March 31, 2022, were collected, following standard clinical specimen collection protocols. Repeated strains of the same patient at the same hospitalization episode were excluded. The sputum samples were taken by a disposable sterile suction tube under negative pressure and sent for microscopic examination within 24 hours after admission. Sputum quality was considered adequate if it contained  $\geq 25$  leukocytes and  $\leq 10$  epithelial cells under low magnification. The Ethics Committee of Hainan Maternal and Child Health Hospital and Hainan Medical University approved our sampling and study. This study did not involve any medical intervention of any patients. The guardians of all patients were provided full information about this study and all of them signed a consent form. The study cohort consisted of 2994 males and 2023 females, of whom 1638 patients were less than 1 month old, 1762 patients were 1 month to 1 year old, 1403 patients were 2 to 5 years old, and 214 patients were 6 to 14 years old ([Table S1](#)).

### Identification of Bacterial Species

To identify the bacteria, we plated the specimens on Columbia blood plate and chocolate plate.<sup>25</sup> The plates were cultured overnight at 35°C in a 5% CO<sub>2</sub> incubator. Actively growing and morphologically distinct colonies on each plate were identified to the species level using the VITEK 2 Compact microbial identification system (BioMérieux, France). The strains were stored in a –80°C freezer until being revived for antimicrobial susceptibility testing.

### Antimicrobial Susceptibility Testing (AST)

For each bacterial isolate that we obtained from each of the patients, we determined its susceptibility to multiple selected antimicrobial agents. These selected agents differed among species with isolates from each species tested for their susceptibilities to a panel of the most commonly used antimicrobial drugs in China for treating the respective infections

caused by each bacterial species. We used the Kirby-Bauer (KB) disk diffusion method to determine the antimicrobial susceptibilities of strains of *H. influenzae* and *M. catarrhalis*. For strains of other bacterial species, we used the VITEK 2 Compact automatic system with the AST-GN/GP cards (bioMérieux, France). The specific antibiotics tested for each species are shown in Tables 1 and 2. For the KB disk diffusion method, the disks (Oxoid Ltd., Basingstoke, UK) were placed onto Mueller–Hinton agar (Oxoid Ltd., Basingstoke, UK) in accordance with the Clinical and Laboratory Standards Institute (CLSI) 2021 guidelines.<sup>26</sup> *H. influenzae* ATCC49247 and *S. aureus* ATCC29213 were used for quality controls. CRE strains were defined as strains of Enterobacteriaceae that were resistant to either ertapenem and/or imipenem.

## β-Lactamase Test

The nitrocefin discs were used to detect β-lactamase activity, following established protocol.<sup>26</sup> A positive result was defined as a disk color change from white to red. A negative result was defined as no color change. Strains *S. aureus* ATCC29213 and *S. aureus* ATCC25923 were used for positive and negative controls.

**Table 1** Antibiotic Resistance Rates of Gram-Positive Bacteria Analyzed in This Study

Bacteria (No. of Strains)	PEN	OX	AMP	ERY	DA	SXT	VAN	LNZ	MEM	CRO	GM
<i>S. pneumoniae</i> (128)	0	–	–	128 (100)	–	120 (93.8)	0	0	0	51 (39.8)	–
<i>S. agalactiae</i> (13)	0	–	0	–	12 (92.3)	–	0	0	–	–	–
<i>S. aureus</i> (89)	70 (78.7)	20 (23.6)	–	22 (24.7)	20 (22.5)	7 (7.9)	0	0	–	–	–
<i>S. haemolyticus</i> (3)	3 (100)	3 (100)	–	3 (100)	1 (33.3)	2 (66.7)	0	0	–	–	–
<i>E. faecalis</i> (1)	0	–	0	0	–	–	0	–	–	–	0

**Notes:** The numbers in table refer to the total number of isolates showing resistance (R) and intermediate (I) susceptibility for each species-antibiotic combination. The numbers in parenthesis indicate the percentages of the (R+I) isolates in the total sample of each species-antibiotic combination.

**Abbreviations:** –, not available; PEN, penicillin; OX, oxacillin; AMP, ampicillin; ERY, erythromycin; DA, clindamycin; SXT, trimethoprim-sulfamethoxazole; VAN, vancomycin; LNZ, Linezolid; MEM, meropenem; CRO, ceftriaxone; GM, gentamicin.

**Table 2** Antibiotic Resistance Rates of Gram-Negative Bacteria Analyzed in This Study

Bacteria (Number of Isolates)	AMP	SAM	TZP	CZ	CRO	CAZ	FEP	IPM	ATM	SXT	TOB	AK
<i>E. coli</i> (89)	61 (68.5)	47 (52.8)	0	21 (23.6)	19 (21.4)	18 (20.2)	1 (1.1)	0	17 (19.1)	26 (29.2)	19 (21.4)	1 (1.1)
<i>K. pneumoniae</i> (82)	–	15 (18.3)	1 (1.2)	11 (13.4)	7 (8.5)	9 (10.9)	1 (1.2)	1 (1.2)	4 (4.9)	11 (13.4)	1 (1.2)	0
<i>K. oxytoca</i> (9)	–	0	0	3 (33.3)	0	0	0	0	0	0	0	0
<i>A. baumannii</i> (31)	–	0	–	–	11 (35.5)	0	0	0	–	2 (6.5)	0	0
<i>A. junii</i> (3)	–	0	–	–	0	0	0	0	–	0	0	0
<i>P. aeruginosa</i> (28)	–	–	0	–	–	0	0	0	–	–	0	0
<i>P. luteola</i> (2)	–	–	0	–	0	0	0	0	–	0	0	0
<i>P. mendocina</i> (1)	–	–	0	–	1 (100)	1 (100)	0	0	–	0	0	0
<i>E. cloacae</i> (18)	–	–	0	–	0	0	0	0	0	0	0	0
<i>E. aerogenes</i> (12)	–	–	0	–	1 (8.3)	1 (8.3)	1 (8.3)	0	1 (8.3)	0	0	0
<i>E. gergoviae</i> (1)	–	–	0	–	0	0	0	0	0	0	0	0
<i>S. marcescens</i> (6)	–	–	0	–	0	0	0	0	0	0	0	0
<i>S. fonticola</i> (1)	–	–	0	–	1 (100)	1 (100)	0	0	1 (100)	0	0	0
<i>C. koseri</i> (5)	–	–	–	0	0	0	0	0	0	0	0	0
<i>R. planticola</i> (2)	–	0	0	0	0	0	0	0	0	0	0	0
<i>P. mirabilis</i> (1)	–	0	0	–	0	0	0	0	0	1 (100)	0	0
<i>Salmonella</i> spp. (1)	0	–	–	–	0	0	–	–	–	0	–	–

**Notes:** The numbers in table refer to the total number of isolates showing resistance (R) and intermediate (I) susceptibility for each species-antibiotic combination. The numbers in parenthesis indicate the percentages of the (R+I) isolates in the total sample of each species-antibiotic combination.

**Abbreviations:** –, not available; AMP, ampicillin; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam; CZ, ceftazidime; FEP, cefepime; IPM, imipenem; ATM, aztreonam; SXT, trimethoprim-sulfamethoxazole; TOB, tobramycin; AK, amikacin.

## Extended-Spectrum $\beta$ -Lactamase Test

For certain groups of bacteria, their ability to produce extended-spectrum  $\beta$ -lactamases was determined by means of a three-disk synergy test (with cefotaxime and cefotaxime/clavulanic acid, ceftazidime, and ceftazidime/clavulanic acid, cefepime and cefepime/clavulanic acid). Strains positive for the production of extended-spectrum  $\beta$ -lactamases were those that showed a greater than or equal to eightfold decrease in MICs for cefotaxime or ceftazidime when tested in combination with clavulanic acid, when compared with their MICs without clavulanic acid, following the Clinical and Laboratory Standards Institute (CLSI) 2021 guidelines.<sup>26</sup>

## Analyses of Data

All statistical comparisons among samples were conducted in GraphPad Prism 8 using the chi-square test. P value <0.05 was considered statistically significant.

## Results

Among the 5017 respiratory tract specimens from hospitalized children with pneumonia, we successfully isolated 996 bacterial strains, yielding an overall 19.9% isolation rate for bacteria. [Table S1](#) summarizes the bacteria carriage rates in the respiratory tract among host groups from Haikou Maternal and Child Health Hospital, of different sexes, ages, and different seasons. Our analyses revealed no statistically significant difference in bacteria isolation rates between the two sexes (P = 0.402). However, significant differences were found among the age groups (less than 1 month old, 1 month to 1 year old, 2 to 5 years old, and 6 to 14 years old) (P = 0.000); and among the four seasons (spring, summer, autumn and winter) (P = 0.000). Specifically, patients aged 1 month to 1 year old had the highest bacteria carriage rate (29.5%), followed by those aged 2 to 5 years old (22.7%), and those aged 6 to 14 years old (9.8%), patients aged less than 1 month old had the lowest bacteria carriage rate (8.4%). Pairwise age-group comparisons revealed that except between the <1 month old and the 6 to 14 years old (P > 0.05), all other age groups comparisons showed statistically significant differences in their bacterial carriage rates (P < 0.05). Among the four seasons, the winter samples had the highest bacterial carriage rate (26.2%), the summer samples had the lowest bacterial carriage rate (16.7%), and the other two seasons (spring and autumn) were in-between, at 20.4% and 18.4%, respectively.

We found no statistically significant difference in species composition between bacteria samples from the two sex groups (P = 0.949) ([Figure 1](#)). However, bacteria populations from the four age groups ([Figure 2](#)) and four seasons ([Figure 3](#)) differed significantly in their bacteria species distributions (P < 0.01 in both comparisons). Specifically, the samples from the 2 to 5 years old analyzed here had a significantly higher percentage of *H. influenzae* (55.2%) than those from less than 1 month (3.6%). In contrast, samples from less than 1 month had a significantly higher percentage of *E. coli* (27.0%) than those from 2 to 5 years old (0.3%) and 6 to 14 years old (0.0%) ([Figure 2](#)). The samples from spring and winter had the higher percentage of *H. influenzae* (45.0% and 47.4%) than those from summer and autumn (25.6% and 24.4%) ([Figure 3](#)).

## Bacteria Isolates

The 996 bacteria isolates belonged to 24 species. Among the 996 isolates, 234 were Gram-positive bacteria (23.5%) and 762 were Gram-negative bacteria (76.5%). Based on their overall frequencies, from the most common to the least common in our sample, the 24 species were *H. influenzae* (356 isolates, 35.7%), *S. pneumoniae* (128, 12.9%), *M. catarrhalis* (114, 11.5%), *E. coli* (89, 8.9%), *S. aureus* (89, 8.9%), *K. pneumoniae* (82, 8.2%), *A. baumannii* (31, 3.1%), *P. aeruginosa* (28, 2.8%), *Enterobacter cloacae* (18, 1.8%), *S. agalactiae* (13, 1.3%), *Enterobacter aerogenes* (12, 1.2%), *Klebsiella oxytoca* (9, 0.9%), *Serratia marcescens* (6, 0.6%), *Citrobacter koseri* (5, 0.5%), *Acinetobacter junii* (3, 0.3%), *S. haemolyticus* (3, 0.3%), *Pseudomonas luteola* (2, 0.2%), *Raoultella planticola* (2, 0.2%), and one each of *Enterococcus faecalis*, *Serratia fonticola*, *Pseudomonas mendocina*, *Proteus mirabilis*, *Enterobacter gergoviae* and *Salmonella* spp, each accounting for 0.1%, respectively ([Table S1](#)).




Figure 1 Detection rate of respiratory tract bacteria by gender in children with pneumonia.





Figure 2 Detection rate of respiratory tract bacteria in different age groups.



**Figure 3** Detection rate of respiratory tract bacteria in different seasons.

## Antimicrobial Susceptibility Profile

The commonly prescribed antimicrobial drugs for clinical use in China were selected to determine the susceptibility pattern for each bacterial isolates obtained in this study. A total of 702 strains (70.5%) showed with the resistant (R) and/or intermediate (I) phenotypes to at least one of the tested drugs. The details are follows.

### Gram-Positive Bacteria

All strains of the five Gram-positive bacteria (*S. pneumoniae*, *S. aureus*, *S. agalactiae*, *S. haemolyticus* and *E. faecalis*) were tested for their susceptibilities to antibiotics by the VITEK 2 Compact automatic system with GP cards. The summary results of antimicrobial susceptibility testing of these five species are presented in [Table 1](#). Below are brief descriptions for each of the five species.

#### *S. pneumoniae*

All the 128 *S. pneumoniae* strains were tested for their susceptibilities to the following seven antibiotics: penicillin, erythromycin, trimethoprim-sulfamethoxazole, vancomycin, linezolid, meropenem, and ceftriaxone ([Table 1](#)). All the 128 *S. pneumoniae* strains were resistant to erythromycin. The rates of resistance to trimethoprim-sulfamethoxazole and ceftriaxone were 93.8% (120/128), and 39.8% (51/128), respectively. All the *S. pneumoniae* strains were sensitive to penicillin, vancomycin, linezolid, and meropenem ([Table 1](#)).

#### *S. aureus* and *S. haemolyticus*

All the 89 *S. aureus* strains and three *S. haemolyticus* strains were tested for their susceptibilities to the following seven antibiotics: penicillin, oxacillin, erythromycin, clindamycin, trimethoprim-sulfamethoxazole, vancomycin, and linezolid. The *S. aureus* and *S. haemolyticus* strains showed different resistance rates to five of the seven drugs but all strains were sensitive to linezolid, and vancomycin. The AMR rates of *S. aureus* to the five drugs, from the highest to lowest, were penicillin (78.7%, 70/89), erythromycin (24.7%, 22/89), oxacillin (MRSA) (22.5%, 20/89), clindamycin (22.5%, 20/89), and trimethoprim-sulfamethoxazole (7.9%, 7/89) ([Table 2](#)). All three *S. haemolyticus* strains were resistant to penicillin,

erythromycin, and oxacillin, two *S. haemolyticus* strains were resistant to trimethoprim-sulfamethoxazole and one *S. haemolyticus* strain was resistant to clindamycin (Table 1).

### *S. agalactiae* and *E. faecalis*


All the 13 *S. agalactiae* strains were tested for their susceptibilities to the following five antibiotics: penicillin, ampicillin, clindamycin, vancomycin, and linezolid. Our *S. agalactiae* population showed a high resistance rate to clindamycin (92.3%, 12/13), but all 13 strains were sensitive to the other four drugs (Table 1). The *E. faecalis* strain was sensitive to all the tested five drugs: penicillin, ampicillin, erythromycin, vancomycin, and gentamicin (Table 1).

## Gram-Negative Bacteria

The *H. influenzae* and *M. catarrhalis* strains were all tested for their susceptibility to antibiotics by the KB disk diffusion method. For other Gram-negative bacterial strains, including those of *E. coli*, *K. pneumoniae*, *A. baumannii*, *P. aeruginosa*, *E. cloacae*, *E. aerogenes*, *K. oxytoca*, *S. marcescens*, *C. koseri*, *A. junii*, *P. Luteola*, *R. planticola*, *S. fonticola*, *P. mendocina*, *P. mirabilis*, *E. gergoviae* and *Salmonella* spp. their antibiotic susceptibilities were determined by the VITEK 2 Compact automatic system with GN cards. The summary results of these tests are presented in Figures 4, 5, and Table 2.


### *H. influenzae* and *M. catarrhalis*

All the 356 *H. influenzae* strains were tested for their susceptibilities to the following seven antibiotics: ampicillin, amoxicillin-clavulanic acid, ceftriaxone, cefuroxime, meropenem, trimethoprim-sulfamethoxazole, and azithromycin (Figure 4). Among the 356 strains, 322 (90.4%) showed the R and/or I phenotypes to at least one of the seven drugs. The overall resistance rates of *H. influenzae* to the seven drugs, from the highest to lowest, were trimethoprim-sulfamethoxazole (80.3%, 286/356), ampicillin (76.7%, 273/356), cefuroxime (58.4%, 208/356), azithromycin (29.5%, 105/356), amoxicillin-clavulanic acid (18.3%, 65/356), ceftriaxone (5.3%, 19/356), and meropenem (0.6%, 2/356) (Figure 4).



**Figure 4** AMR rates of the *H. influenzae* population in this study.

**Abbreviations:** AMP, ampicillin; AMC, amoxicillin-clavulanic acid; CXM, cefuroxime; CRO, ceftriaxone; MEM, meropenem; SXT, trimethoprim-sulfamethoxazole; AZM, azithromycin.



**Figure 5** AMR rates of the *M. catarrhalis* population in this study.

**Abbreviations:** AMC, amoxicillin-clavulanic acid; SXT, trimethoprim-sulfamethoxazole; AZM, azithromycin; ERY, erythromycin; CLA, clarithromycin; TET, tetracycline.

All the 114 *M. catarrhalis* strains were tested for their susceptibilities to the following six drugs: amoxicillin-clavulanic acid, trimethoprim-sulfamethoxazole, azithromycin, erythromycin, clarithromycin, and tetracycline (Figure 5). All the *M. catarrhalis* strains were sensitive to tetracycline and clarithromycin, while the *M. catarrhalis* strains showed different resistance rates to other four drugs: amoxicillin-clavulanic acid (1.8%, 2/114), trimethoprim-sulfamethoxazole (29.8%, 34/114), azithromycin (41.2%, 47/114), and erythromycin (44.7%, 51/114) (Figure 5). In addition, 60.5% (69/114) of *M. catarrhalis* strains and 42.9% (153/356) of *H. influenzae* strains produced  $\beta$ -lactamases.

### *E. coli*

All the 89 *E. coli* strains were tested for their susceptibilities to the following 12 antibiotics: ampicillin, ampicillin-sulbactam, piperacillin-tazobactam, ceftazidime, cefepime, imipenem, aztreonam, trimethoprim-sulfamethoxazole, tobramycin, and imipenem (Table 2). The *E. coli* strains showed different resistance rates to 10 of the 12 antibiotics except for amikacin and piperacillin-tazobactam where no resistant strain was isolated. The resistance rates of *E. coli* to the 10 drugs from the highest to lowest were ampicillin (68.5%, 61/89), ampicillin-sulbactam (52.8%, 47/89), trimethoprim-sulfamethoxazole (29.2%, 26/89), ceftazidime (23.6%, 21/89), ceftriaxone (21.4%, 19/89), tobramycin (21.4%, 19/89), ceftazidime (20.2%, 18/89), aztreonam (19.1%, 17/89), cefepime (1.1%, 1/89), and amikacin (1.1%, 1/89). In addition, 19.1% (17/89) *E. coli* strains produced extended spectrum  $\beta$ -lactamases.

### *K. pneumoniae* and *K. oxytoca*

All the 82 *K. pneumoniae* strains and nine *K. oxytoca* strains were tested for their susceptibilities to the following 11 antibiotics: ampicillin-sulbactam, piperacillin-tazobactam, ceftazidime, cefepime, imipenem, aztreonam, trimethoprim-sulfamethoxazole, tobramycin, and amikacin (Table 2). All the *K. pneumoniae* strains were sensitive to amikacin. One each of the 82 *K. pneumoniae* strains was resistant to piperacillin-tazobactam, cefepime, imipenem (CRE) and piperacillin-tazobactam respectively. The resistance rates of *K. pneumoniae* to the other six drugs from the highest to lowest were ampicillin-sulbactam (18.3%, 15/82), ceftazidime (13.4%, 11/82), trimethoprim-sulfamethoxazole (13.4%, 11/82), ceftazidime (10.9%, 9/82), ceftriaxone (8.5%, 7/82), and aztreonam (4.9%, 4/82). The CRE strains were resistant to nine of the 11 drugs except tobramycin and amikacin. 6.1% (5/82) *K. pneumoniae*



produced extended-spectrum  $\beta$ -lactamases. Three of the nine (33.3%) *K. oxytoca* strains were resistant to cefazolin. All the nine *K. oxytoca* strains were sensitive to the other ten drugs.

#### *A. baumannii* and *A. junii*

All the 31 *A. baumannii* strains and three *A. junii* were tested for their susceptibilities to the following eight antibiotics: ampicillin-sulbactam, ceftriaxone, ceftazidime, cefepime, imipenem, trimethoprim-sulfamethoxazole, tobramycin, and amikacin (Table 2). Two of the 31 (6.5%) *A. baumannii* strains were resistant to trimethoprim-sulfamethoxazole, 11 (35.5%) were resistance to ceftriaxone, while the other *A. baumannii* strains were sensitive to the other six drugs. All three *A. junii* strains were sensitive to all the eight drugs.

#### *P. aeruginosa*, *P. luteola* and *P. mendocina*

All the 28 *P. aeruginosa* strains were tested for their susceptibilities to the following six antibiotics: piperacillin-tazobactam, ceftazidime, cefepime, imipenem, tobramycin, and amikacin (Table 2). Two *P. luteola* and one *P. mendocina* strains were tested for their susceptibilities to the following eight antibiotics: piperacillin-tazobactam, ceftriaxone, ceftazidime, cefepime, imipenem, trimethoprim-sulfamethoxazole, tobramycin, and amikacin. The *P. mendocina* strain was resistant to ceftriaxone and ceftazidime. The other tested strains were all sensitive to the tested drugs.

#### *E. cloacae*, *E. aerogenes* and *E. gergoviae*

All the 18 *E. cloacae*, 12 *E. aerogenes* and one *E. gergoviae* strains were tested for their susceptibilities to the following nine antibiotics: piperacillin-tazobactam, ceftriaxone, ceftazidime, cefepime, imipenem, aztreonam, trimethoprim-sulfamethoxazole, tobramycin, and amikacin (Table 2). One *E. aerogenes* isolate was resistant to ceftriaxone, ceftazidime, cefepime, and aztreonam. Other tested strains were all sensitive strains to all tested antibiotics.

#### *S. marcescens* and *S. fonticola*

All the six *S. marcescens* and one *S. fonticola* strains were tested for their susceptibilities to the same antibiotics as *Enterobacter sp.* above (Table 2). The *S. fonticola* strain was resistant to ceftriaxone, ceftazidime, and aztreonam but sensitive to other six drugs. All the six *S. marcescens* strains were sensitive to the nine tested antibiotics.

#### Others

Five *C. koseri*, two *R. planticola*, one *P. mirabilis*, and one *Salmonella* strains were tested for their susceptibilities to different drugs (Table 2). All the strains were sensitive to the tested drugs except the *P. mirabilis* strain which was resistant to trimethoprim-sulfamethoxazole.

## Discussion

Pneumonia is a major cause of morbidity and mortality. According to the 2015 and 2016 GBD data, the main causes of pneumonia deaths in children were bacteria.<sup>1,27</sup> Similar to those reported from Chengdu (southwest China) and Xiamen (southeast China),<sup>25,28</sup> the detected bacterial species in this study mainly belonged to Gram-negative taxa, and that the 1 month to 1 year old and 2 to 5 years old groups had higher bacteria carriage rates than those of less than 1 month and the 6 to 14 years old groups ( $p = 0.000$ ). However, no statistically significant difference in bacterial species composition and isolate rate was found between the two sex groups. Our results are different from a study in India that demonstrated boys under 5 years old had a higher incidence of respiratory tract infection than girls.<sup>29</sup>

*H. influenzae*, *S. pneumoniae*, and *M. catarrhalis* are the top three bacterial pathogens colonizing the lower respiratory tract of children with pneumonia. A previous study showed that these three bacteria were positively correlated with each other in their carriage rates at the population level.<sup>30</sup> However, differences among age groups were found for several species, similar to two previous reports.<sup>27,31</sup> For example, in our sample, *H. influenzae* (55.2%) were mainly isolated from the 2 to 5 years old group while only 3.6% was found in the less than 1 month age group. In contrast, samples from less than 1 month old had a significantly higher percentage of *E. coli* (27.0%) than those from 2 to 5 years old (0.3%) and 6 to 14 years old (0.0%).

Our results also observed significant influence of seasons on species distribution. For example, the samples from spring and winter had higher percentages of *H. influenzae* (45.0% and 47.4%) than those from summer and autumn (25.6% and 24.4%). Our results contrast those reported recently of a retrospective study from Chengdu, China. In that study, *H. influenzae* was detected more frequently in spring than other species, while *S. pneumoniae* and *M. catarrhalis* were detected more frequently in winter.<sup>27</sup> Seasonal differences have been found in many fungal pathogens, largely related to differences in temperature and moisture among seasons and the impact of those differences on fungal growth and reproduction in both our indoor and outdoor living environments.<sup>10,32</sup>

AMR is a recognized global threat and increases the risk of infection-related death for patients of all age groups, including children. In our study, a total of 702 strains (70.5%) showed the R and/or I phenotypes to at least one of the tested drugs in this study. Our results suggest that susceptibility testing should be implemented before antibiotic treatment in Hainan to improve treatment success. The main bacteria detected in our cohort was *H. influenzae* and we observed high AMR rates of this species to sulfamethoxazole (80.3%) and ampicillin (76.9%), similar to those reported in southern parts of Mainland China<sup>27,28</sup> Ampicillin is a historical drug of choice for treating *H. influenzae* infection, but in recent years, ampicillin resistance has increased substantially,<sup>33–37</sup> suggesting that ampicillin should no longer be the first-line treatment for infections caused by *H. influenzae* in China. Furthermore, strains of *H. influenzae* isolated here showed variable rates of resistance to 5 other commonly used antibiotics (Figure 4), with 42.9% of these strains producing  $\beta$ -lactamases. Interestingly, though the rate of  $\beta$ -lactamase production was high, it was lower than that reported in a national survey in China by the Infectious Disease Surveillance of Pediatrics (ISPED) program during 2016–2020.<sup>38</sup>

The second most common bacterium was *S. pneumoniae* and we observed all strains of this species being resistant to erythromycin. In addition, we observed a high frequency resistance to trimethoprim-sulfamethoxazole. Interestingly, there was a low frequency of resistance to ceftriaxone and all *S. pneumoniae* strains in our collection were extremely sensitive to penicillin, vancomycin, linezolid, and meropenem (Table 2). These data are generally consistent with those reported previously.<sup>27,28,35</sup> Together, our results suggest that penicillin, vancomycin, linezolid, and meropenem can be used as the first-line antibiotics for the treatment of pneumoniae caused by *S. pneumoniae* in Hainan.

The third most common bacterial species was *M. catarrhalis* and we observed that 60.5% of *M. catarrhalis* strains produced  $\beta$ -lactamases. This rate is far lower than previously reported by ISPED (>95%).<sup>37</sup> However, all the *M. catarrhalis* strains were sensitive to tetracycline and clarithromycin, and with different degrees of resistance to amoxicillin-clavulanic acid, trimethoprim-sulfamethoxazole, azithromycin, and erythromycin.

Among the 89 *S. aureus* and three *S. haemolyticus* strains isolated in our study, 22.5% and 100% were resistant to oxacillin, respectively. A similar rate was reported by Zhu et al during 2018–2020 where 27% of *S. aureus* detected in the lower respiratory tract of children in Chengdu, southwest China were MRSA and with an increasing trend of resistance over the three years.<sup>27</sup> Reports from Japan suggested that the rapid spread of *S. aureus* carrying the resistance gene in the environment was associated with increased MRSA detection rate in hospitals.<sup>39</sup> Similarly, reports from Spain showed that the use of antibiotics in animal husbandry promoted the spread of *Staphylococcus* antibiotic resistance genes in the environment and wildlife.<sup>40</sup> We also found the oxacillin-resistant *S. aureus* and oxacillin-resistant *S. haemolyticus* strains were also resistant to penicillin and were more likely to be resistant to other antibiotics than the oxacillin-sensitive *S. aureus* and oxacillin-sensitive *S. haemolyticus*. Interestingly, all *S. aureus* and *S. haemolyticus* strains in our study were sensitive to vancomycin and linezolid. Our results suggest that these two drugs can be used as first-line drugs for treating infections caused by MRSA and MRSH in Hainan.

*E. coli* and *K. pneumoniae* were the most common species producing extended-spectrum  $\beta$ -lactamases. In this study, we found that the frequency of extended-spectrum  $\beta$ -lactamases production from *E. coli* and *K. pneumoniae* were 19.1% and 6.1%, respectively. These rates are far lower than those reported in the previous studies.<sup>41,42</sup> Studies conducted by Wang et al<sup>43</sup> and Rodriguez-Bano et al<sup>44</sup> showed statistically significant relationship between age groups and the percentage of extended-spectrum  $\beta$ -lactamases producers, with the oldest age group having a greater proportion of extended-spectrum  $\beta$ -lactamases-producing strains. Over half of the *E. coli* strains in our sample were resistant to ampicillin and ampicillin-sulbactam, similar to those reported in a previous study.<sup>28</sup> However, our *E. coli* sample showed a lower frequency of resistance to other 10 antibiotics (trimethoprim-sulfamethoxazole, cefazolin, ceftriaxone, tobramycin, ceftazidime, aztreonam, cefepime, amikacin, and piperacillin-tazobactam) than previous reports<sup>27,28,38</sup> (Table 2).

Among all strains isolated here, the CRE strain showed the broadest antibiotic resistance profile, being resistant to nine of the 11 tested drugs except tobramycin and amikacin (Table 2).

## Conclusion

In conclusion, our analyses of the distribution and drug resistance characteristics of bacterial pathogens revealed significant age and seasonal patterns of bacterial infection epidemiology in children with pneumonia in Hainan. High drug resistance rates were observed for most bacterial species to several of the antibiotics. Our results call for greater effects in vaccination, hand hygiene, strengthening of personal protective measures, and aseptic operation of invasive medical treatment to reduce the spread of drug-resistant pathogens. In addition, the highly variable AMR rates among the pathogen species-antibiotic combinations call for the development of rapid and accurate detection of both the pathogens and their antibiotic susceptibilities in individual jurisdictions.<sup>37</sup> Such data could help shorten decision-making and improve treatment outcomes against these pathogens.

## Abbreviations

MDR, Multidrug-resistant; MRSA, methicillin (oxacillin) resistant *Staphylococcus aureus*; MRSH, methicillin (oxacillin) resistant *Staphylococcus haemolyticus*; CRE, Carbapenem resistant *Enterobacteriaceae*; VRE, Vancomycin resistant *Enterococci*; KB, Kirby-Bauer disk diffusion; CLSI, Clinical and Laboratory Standards Institute; AMR, Antimicrobial resistance; ISPED, Infectious Disease Surveillance of Pediatrics; *H. influenza*, *Hemophilus influenza*; *S. pneumoniae*, *Streptococcus pneumoniae*; *M. catarrhalis*, *Moraxella catarrhalis*; *E. coli*, *Escherichia coli*; *S. aureus*, *Staphylococcus aureus*; *K. pneumoniae*, *Klebsiella pneumoniae*; *A. baumannii*, *Acinetobacter baumannii*; *P. aeruginosa*, *Pseudomonas aeruginosa*; *P. aeruginosa*, *Pseudomonas aeruginosa*; *S. agalactiae*, *Streptococcus agalactiae*; *S. agalactiae*, *Streptococcus agalactiae*; *E. aerogenes*, *Enterobacter aerogenes*; *K. oxytoca*, *Klebsiella oxytoca*; *S. marcescens*, *Serratia marcescens*; *C. koseri*, *Citrobacter koseri*; *A. junii*, *Acinetobacter junii*; *P. luteola*, *Pseudomonas luteola*; *R. planticola*, *Raoultella planticola*; *E. faecalis*, *Enterococcus faecalis*; *S. fonticola*, *Serratia fonticola*; *P. mendocina*, *Pseudomonas mendocina*; *P. mirabilis*, *Proteus mirabilis*; *E. gergoviae*, *Enterobacter gergoviae*; *E. cloacae*, *Enterobacter cloacae*.

## Ethics Statement

The study complied with the Declaration of Helsinki.

## Funding

Financial support for this project came from the National Natural Science Foundation of China (Grant No. 31860035), and Natural Science Foundation of Hainan Province (Grant No.822RC708, 2019RC227 and 819MS142).

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. McAllister DA, Liu L, Shi T, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. *Lancet Glob Health*. 2019;7(1):e47–e57. doi:10.1016/S2214-109X(18)30408-X
2. Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals [published correction appears in *Lancet*. 2017 May 13;389(10082):1884]. *Lancet*. 2016;388(10063):3027–3035. doi:10.1016/S0140-6736(16)31593-8
3. Feng XL, Theodoratou E, Liu L, et al. Social, economic, political and health system and program determinants of child mortality reduction in China between 1990 and 2006: a systematic analysis. *J Glob Health*. 2012;2:010405. doi:10.7189/jogh.02.010405
4. World Health Organization. *Global and Regional Immunization Profile*. Geneva: World Health Organization; 2017.
5. Rudan I, O'Brien KL, Nair H, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. *J Glob Health*. 2013;3(1):010401. doi:10.7189/jogh.03.010401
6. Zar HJ, Andronikou S, Nicol MP. Advances in the diagnosis of pneumonia in children. *BMJ*. 2017;358:j2739. doi:10.1136/bmj.j2739
7. Chintu C, Mudenda V, Lucas S, et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. *Lancet*. 2002;360(9338):985–990. doi:10.1016/S0140-6736(02)11082-8

8. Santoso P, Sung M, Hartantri Y, et al. MDR pathogens organisms as risk factor of mortality in secondary pulmonary bacterial infections among COVID-19 patients: observational studies in two referral hospitals in West Java, Indonesia. *Int J Gen Med.* 2022;15:4741–4751. doi:10.2147/IJGM.S359959
9. Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence-implications for human health and treatment perspectives. *EMBO Rep.* 2020;21(12):e51034. doi:10.15252/embr.202051034
10. Xu J. Assessing global fungal threats to humans. *mLife.* 2022;1(3):223–240. doi:10.1002/mlf2.12036
11. Woolhouse M, Waugh C, Perry MR, Nair H. Global disease burden due to antibiotic resistance - state of the evidence. *J Glob Health.* 2016;6:010306. doi:10.7189/jogh.06.010306
12. Tiri B, Sensi E, Marsiliani V, et al. Antimicrobial stewardship program, COVID-19, and infection control: spread of carbapenem-resistant *Klebsiella pneumoniae* colonization in ICU COVID-19 patients. What did not work? *J Clin Med.* 2020;9:E2744.
13. Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. *Antimicrob Resist Infect Control.* 2020;9:153. doi:10.1186/s13756-020-00819-1
14. Contou D, Claudinon A, Pajot O, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. *Ann Intensive Care.* 2020;10:119. doi:10.1186/s13613-020-00736-x
15. Sharifipour E, Shams S, Esmkhani M, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. *BMC Infect Dis.* 2020;20:646. doi:10.1186/s12879-020-05374-z
16. Fu Y, Yang Q, Xu M, et al. Secondary bacterial infections in critical ill patients with coronavirus disease 2019. *Open Forum Infect Dis.* 2020;7:ofaa220.
17. Nori P, Szymczak W, Puius Y, et al. Emerging co-pathogens: New Delhi metallo- $\beta$ -lactamase producing Enterobacteriaceae infections in New York City COVID-19 patients. *Int J Antimicrob Agents.* 2020;106179. doi:10.1016/j.ijantimicag.2020.106179
18. Farfour E, Lecuru M, Dortet L, et al. Carbapenemase-producing Enterobacterales outbreak: another dark side of COVID-19. *Am J Infect Control.* 2020;48:1533–1536. doi:10.1016/j.ajic.2020.09.015
19. Posteraro B, Torelli R, Vella A, et al. Pan-echinocandin-resistant *Candida glabrata* bloodstream infection complicating COVID-19: a fatal case report. *J Fungi.* 2020;6:163. doi:10.3390/jof6030163
20. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant *Candida auris* infections in critically ill coronavirus disease patients, India, April–July 2020. *Emerg Infect Dis.* 2020;26:2694–2696. doi:10.3201/eid2611.203504
21. Mohamed A, Hassan T, Trzos-Grzybowska M, et al. Multi-triazole-resistant *Aspergillus fumigatus* and SARS-CoV-2 co-infection: a lethal combination. *Med Mycol Case Rep.* 2021;31:11–14. doi:10.1016/j.mmcr.2020.06.005
22. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. *Clin Microbiol Infect.* 2020;26:1395–1399. doi:10.1016/j.cmi.2020.06.025
23. Lai CC, Chen SY, Ko WC, Hsueh PR. Increased antimicrobial resistance during the COVID-19 pandemic. *Int J Antimicrob Agents.* 2021;57(4):106324. doi:10.1016/j.ijantimicag.2021.106324
24. Centers for Disease Control and Prevention. Multidrug-resistant organisms (MDRO) management. Available from: <https://www.cdc.gov/infection-control/guidelines/mdro/>. Accessed September 19, 2022.
25. Zhu X, Ye T, Zhong H, et al. Distribution and drug resistance of bacterial pathogens associated with lower respiratory tract infection in children and the effect of COVID-19 on the distribution of pathogens. *Can J Infect Dis Med Microbiol.* 2022;1181283. doi:10.1155/2022/1181283
26. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing.* 31st ed. CLSI supplement M100. Wayne, America: Clinical and Laboratory Standards Institute; 2021.
27. GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis.* 2018;18(11):1191–1210. doi:10.1016/S1473-3099(18)30310-4
28. Su DQ, Huang HL, Zhuo ZQ. Pathogen distribution and bacterial resistance in children with severe pneumonia: a single-center retrospective study. *Medicine.* 2021;100(35):e27128. doi:10.1097/MD.00000000000027128
29. Krishnan A, Amarchand R, Gupta V, et al. Epidemiology of acute respiratory infections in children - preliminary results of a cohort in a rural north Indian community. *BMC Infect Dis.* 2015;15:462. doi:10.1186/s12879-015-1188-1
30. Dunne EM, Murad C, Sudigdoadi S, et al. Carriage of *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Staphylococcus aureus* in Indonesian children: a cross-sectional study. *PLoS One.* 2018;13(4):e0195098. doi:10.1371/journal.pone.0195098
31. Musher DM, Jesudasan SS, Barwatt JW, Cohen DN, Moss BJ, Rodriguez-Barradas MC. Normal respiratory flora as a cause of community-acquired pneumonia. *Open Forum Infect Dis.* 2020;7(9):ofaa307. doi:10.1093/ofid/ofaa307
32. Xu J. Origins and spread of plant fungal and oomycete disease outbreaks. *J Plant Protect.* 2022;49(1):283–297.
33. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. *Clin Infect Dis.* 2011;53(7):e25–e76. doi:10.1093/cid/cir531
34. Jochem WC, Razzaque A, Root ED. Effects of health intervention programs and arsenic exposure on child mortality from acute lower respiratory infections in rural Bangladesh. *Int J Health Geogr.* 2016;15(1):32. doi:10.1186/s12942-016-0061-9
35. Troeger C, Forouzanfar M, Rao PC, GBD 2015 LRI Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Infect Dis.* 2017;17(11):1133–1161. doi:10.1016/S1473-3099(17)30396-1
36. Torumkuney D, Chaiwarith R, Reecheaipichitkul W, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2012–14 in Thailand, India, South Korea and Singapore. *J Antimicrob Chemother.* 2016;71(Suppl1):i3–i19. doi:10.1093/jac/dkw073
37. Vaez H, Sahebkar A, Pourfarzi F, Yousefi-Avarvand A, Khademi F. Prevalence of antibiotic resistance of *Haemophilus influenzae* in Iran- a meta-analysis. *Iran J Otorhinolaryngol.* 2019;31(107):349–357. doi:10.22038/ijorl.2019.34363.2137
38. Fu P, Xu H, Jing C, et al. Bacterial epidemiology and antimicrobial resistance profiles in children reported by the ISPED program in China, 2016 to 2020. *Microbiol Spectr.* 2021;9(3):e0028321. doi:10.1128/Spectrum.00283-21
39. Mitumoto-Kaseida F, Murata M, Toyoda K, et al. Clinical and pathogenic features of SCCmec type II and IV methicillin-resistant *Staphylococcus aureus* in Japan. *J Infect Chemother.* 2017;23(2):90–95. doi:10.1016/j.jiac.2016.11.001

40. García LA, Torres C, López AR, Rodríguez CO, Espinosa JO, Valencia CS. *Staphylococcus* spp. from wild mammals in Aragón (Spain): antibiotic resistance status. *J Vet Res*. 2020;64(3):373–379. doi:10.2478/jvetres-2020-0057
41. Hu F, Wang F, Jiang X, et al. Report of CHINET antimicrobial resistance surveillance program in 2015. *Chin J Infect Chemother*. 2016;16(6):685–694.
42. Hu F, Zhu D, Wang F, et al. CHINET surveillance of bacterial resistance across China: report of the results in 2016. *Chin J Infect Chemother*. 2016;17(5):481–491.
43. Wang Y, Zhang Q, Jin Y, Jin X, Yu J, Wang K. Epidemiology and antimicrobial susceptibility profiles of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli* in China. *Braz J Microbiol*. 2019;50(3):669–675. doi:10.1007/s42770-019-00081-7
44. Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al. Community Infections Caused by Extended-Spectrum  $\beta$ -Lactamase-Producing *Escherichia coli*. *Arch Intern Med*. 2008;168(17):1897–1902. doi:10.1001/archinte.168.17.1897

## Infection and Drug Resistance

Dovepress

### Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>